Fig. 2

Inhibition of ferroptosis driver ACSL4 attenuates SSc fibrosis. A Schematic illustration of the treatment schedule. B Representative images of immunohistochemistry staining for ACSL4 of murine lung tissue (× 200, × 800). C, D Western blots of ACSL4 expression level in murine lung tissue. E Relative mRNA expression level of ACSL4 by quantitative PCR (n = 6). F Representative photos of the local injected murine skin of each group. G H&E and Masson’s staining representative images of murine skin and lung tissue, data are summarized in graphs (× 200), (n = 8). H HYP content of skin and lung tissue (n = 6). I Relative mRNA levels of fibrosis markers in each group by quantitative PCR (n = 6). (Data are presented as Mean ± SD *p < 0.05, **p < 0.01, ***p < 0.001, * stands for control versus BLM group; #p < 0.05, ##p < 0.01, ###p < 0.001, #stands for BLM group versus BLM + ROSI-treated group)